伐努赛珠单抗（INN：Vanucizumab；开发代号：RG7221）是一种实验性人源化单克隆抗体，设计用于治疗癌症。[1][2]
伐努赛珠单抗是一种双特异性单克隆抗体，由两条不同的重链和两条不同的轻链组成。该抗体的一个臂结合血管生成素2（Ang2），另一个臂基于贝伐珠单抗（Avastin），结合血管内皮生长因子A（VEGF-A）。该抗体旨在同时抑制VEGF-A和 Ang2，与单独抑制VEGF-A相比，可提供更优异的临床益处。[3]
该药物由基因泰克/罗氏公司开发。
参考资料[编辑]
- ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Vanucizumab, American Medical Association.
- ^ World Health Organization. International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 111 (PDF). WHO Drug Information. 2014, 28 (2).
- ^ Bendell, Johanna C.; Sauri, Tamara; Gracián, Antonio Cubillo; Alvarez, Rafael; López‐López, Carlos; García‐Alfonso, Pilar; Hussein, Maen; Miron, Maria‐Luisa Limon; Cervantes, Andrés; Montagut, Clara; Vivas, Cristina Santos. The McCAVE Trial: Vanucizumab plus mFOLFOX‐6 Versus Bevacizumab plus mFOLFOX‐6 in Patients with Previously Untreated Metastatic Colorectal Carcinoma (mCRC). The Oncologist. 2020-3, 25 (3). ISSN 1083-7159. PMC 7066709
. PMID 32162804. doi:10.1634/theoncologist.2019-0291.
